JNJ FINANCIAL STATEMENTS

Johnson & Johnson — balance sheet, income statement and cash flow trends

JNJJohnson & Johnson

🇺🇸 USA · US · Healthcare · Drug Manufacturers - General

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue96.4 B $+7.9%

Gross Profit66.6 B $+9.2%

Operating Income25.9 B $+17.3%

EBITDA33.5 B $-3.5%

Net Income21 B $-3.5%

Peer Comparison· Drug Manufacturers - General

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
JNJ	7.9%	69.1%	34.8%	21.8%
SAN	3.3%	90.8%	23.4%	22.3%
BAYN	-2.9%	59.3%	7.7%	-4.8%
AZN	9.9%	81.6%	33.7%	17.2%
Industry median	3.3%	70.7%	28.4%	15.0%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
JNJ	7.9%	69.1%	34.8%	21.8%
ABBV	9.5%	70.7%	26.9%	5.8%
LLY	47.4%	83.5%	46.3%	35.0%
MRK	2.5%	75.9%	28.6%	13.6%
AMGN	9.1%	71.5%	44.8%	20.9%
GILD	3.5%	79.4%	48.7%	31.0%
Industry median	3.3%	70.7%	28.4%	15.0%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Equity81.2 B $40%
Current Liabilities57.7 B $29%
Long-term Liabilities62 B $31%

Key Figures

YoY change

Total Assets200.9 B $+3.7%

Total Liabilities119.7 B $+3.6%

Total Equity81.2 B $+3.9%

Cash & ST Investments22.1 B $-43.1%

Total Debt55 B $+5.2%

Net Debt-4.2 B $-130.7%

Peer Comparison· Drug Manufacturers - General

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
JNJ	1.03	67.7%	0.98	40.4%
SAN	1.01	27.5%	1.33	56.9%
BAYN	1.06	134.8%	9.19	26.7%
AZN	0.91	71.7%	1.29	41.5%
Industry median	1.25	94.3%	1.35	28.4%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
JNJ	1.03	67.7%	0.98	40.4%
ABBV	0.80	-1,101.9%	3.75	-4.8%
LLY	1.50	139.0%	1.14	26.8%
MRK	1.30	107.1%	2.31	35.7%
AMGN	1.26	623.8%	2.71	9.9%
GILD	1.97	94.3%	0.85	41.8%
Industry median	1.25	94.3%	1.35	28.4%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow22.9 B $-7.7%

Capital Expenditures5.1 B $-18.1%

Free Cash Flow17.8 B $-4.3%

Dividends Paid-12.5 B $-204.9%

Peer Comparison· Drug Manufacturers - General

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
JNJ	23.7%	18.5%	5.3%	108.7%
SAN	42.9%	34.1%	3.8%	192.2%
BAYN	10.0%	4.4%	5.5%	-209.8%
AZN	23.5%	14.5%	9.0%	136.9%
Industry median	23.7%	18.5%	5.3%	137.9%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
JNJ	23.7%	18.5%	5.3%	108.7%
ABBV	33.8%	33.2%	2.2%	583.2%
LLY	28.3%	18.8%	9.6%	81.0%
MRK	27.3%	21.5%	5.8%	200.2%
AMGN	28.9%	23.1%	5.8%	137.9%
GILD	36.3%	34.4%	1.9%	117.3%
Industry median	23.7%	18.5%	5.3%	137.9%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on JNJ

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.